Exubera Patent Expiration

Exubera is a drug owned by Pfizer Inc. It is protected by 11 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 24, 2020. Details of Exubera's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6582728 Spray drying of macromolecules to produce inhaleable dry powders
Jun, 2020

(4 years ago)

Expired
US6257233 Dry powder dispersing apparatus and methods for their use
May, 2019

(5 years ago)

Expired
US6546929 Dry powder dispersing apparatus and methods for their use
May, 2019

(5 years ago)

Expired
US6685967 Methods and compositions for pulmonary delivery of insulin
Sep, 2018

(6 years ago)

Expired
US5740794 Apparatus and methods for dispersing dry powder medicaments
Apr, 2015

(9 years ago)

Expired
US6543448 Apparatus and methods for dispersing dry powder medicaments
Sep, 2014

(10 years ago)

Expired
US5997848 Methods and compositions for pulmonary delivery of insulin
Mar, 2014

(10 years ago)

Expired
US6423344 Dispersible macromolecule compositions and methods for their preparation and use
Mar, 2014

(10 years ago)

Expired
US6737045 Methods and compositions for the pulmonary delivery insulin
Mar, 2014

(10 years ago)

Expired
US6051256 Dispersible macromolecule compositions and methods for their preparation and use
Mar, 2014

(10 years ago)

Expired
US6592904 Dispersible macromolecule compositions and methods for their preparation and use
Mar, 2014

(10 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Exubera's patents.

Given below is the list of recent legal activities going on the following patents of Exubera.

Activity Date Patent Number
Patent litigations
Expire Patent 10 Jun, 2016 US6737045
Expire Patent 07 Aug, 2015 US6592904
Expire Patent 08 May, 2015 US6546929
File Marked Found 21 Oct, 2004 US6737045
File Marked Lost 17 Aug, 2004 US6737045
Recordation of Patent Grant Mailed 18 May, 2004 US6737045
Patent Issue Date Used in PTA Calculation 18 May, 2004 US6737045
Issue Notification Mailed 29 Apr, 2004 US6737045
Receipt into Pubs 07 Apr, 2004 US6737045
Application Is Considered Ready for Issue 05 Apr, 2004 US6737045


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Exubera and ongoing litigations to help you estimate the early arrival of Exubera generic.

Exubera's Litigations

Exubera been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 24, 2002, against patent number US6685967. The petitioner , challenged the validity of this patent, with PATTON et al as the respondent. Click below to track the latest information on how companies are challenging Exubera's patents.

Last updated on December 10, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6685967 April, 2002 Decision
(23 Jan, 2003)
PATTON et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Exubera is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Exubera's family patents as well as insights into ongoing legal events on those patents.

Exubera's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Exubera's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 24, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Exubera Generics:

There are no approved generic versions for Exubera as of now.

Alternative Brands for Exubera

Exubera which is used for managing diabetes by delivering insulin through inhalation., has several other brand drugs using the same active ingredient (Insulin Recombinant Human). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.






About Exubera

Exubera is a drug owned by Pfizer Inc. It is used for managing diabetes by delivering insulin through inhalation. Exubera uses Insulin Recombinant Human as an active ingredient. Exubera was launched by Pfizer in 2006.

Approval Date:

Exubera was approved by FDA for market use on 27 January, 2006.

Active Ingredient:

Exubera uses Insulin Recombinant Human as the active ingredient. Check out other Drugs and Companies using Insulin Recombinant Human ingredient

Treatment:

Exubera is used for managing diabetes by delivering insulin through inhalation.

Dosage:

Exubera is available in powder form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
3MG/INH POWDER Discontinued INHALATION
1MG/INH POWDER Discontinued INHALATION